



The KabiCare Co-pay Assistance Program

ICATIBANT TERMS AND CONDITIONS

- To receive benefits under the Co-pay Assistance Program, the patient may contact The KabiCare Access Program for current Program Product(s) subject to these Terms and Conditions.
- Patient must be prescribed the Program Product for an FDA-approved indication.
- Patient must have private health insurance that provides coverage for the cost of the Program Product under a pharmacy benefit plan.
- **The Co-pay Assistance Program is not valid for patients covered under Medicaid (including Medicaid patients enrolled in a qualified health plan purchased through a health insurance exchange [marketplace] established by a state government or the federal government), Medicare, a Medicare Part D or Medicare Advantage plan (regardless of whether a specific prescription is covered), TRICARE, CHAMPUS, Puerto Rico Government Health Insurance Plan ("Healthcare Reform"), or any other state or federal medical or pharmaceutical benefit program or pharmaceutical assistance program (collectively, "Government Programs"). The Co-pay Assistance Program is valid for uninsured patients.**
- Patient must have an out-of-pocket cost for the Program Product prior to the expiration date of the Co-pay Assistance Program. The benefit available under the Co-pay Assistance Program is valid for the patient's out-of-pocket cost for the Program Product only. It is not valid for any other out-of-pocket costs (for example, office visit charges or medication administration charges) even if such costs are associated with the administration of the Program Product.
- The benefit available under the Co-pay Assistance Program is limited to the amount the patient's private health insurance company indicates that the patient is obligated to pay for the Program Product, up to a per syringe/annual maximum. The maximum Co-pay Assistance Program benefit per syringe is \$5,000 and \$15,000 per calendar year (January 1 through December 31).
- This benefit is for commercially insured patients only. Uninsured and cash paying patients may be eligible for other types of support not part of the copay program. The Program is limited to a monthly/annual maximum. The maximum Co-pay Assistance Program benefit per syringe is \$150 and \$15,000 per calendar year (January 1 through December 31).
- Patient agrees not to seek reimbursement for all, or any part of the benefit received by the patient through the Co-pay Assistance Program. Patients are responsible for reporting receipt of Co-pay Assistance Program benefits to any insurer, health plan, or other third party who pays for or reimburses any part of the medication cost paid for by the Co-pay Assistance Program, as may be required.
- Patient must be a resident of the United States or the Commonwealth of Puerto Rico. Product must originate and be administered to patient in the United States or the Commonwealth of Puerto Rico.
- The Program may apply to patient out-of-pocket costs incurred for Program subject to annual Program maximum and the applicable Terms and Conditions based on Program Product administration date. Patient or provider may contact The KabiCare Access Program for more information.
- All information applicable to the Co-pay Assistance Program requested on the KabiCare site must be provided, and all certifications must be selected. No other purchase is necessary.
- **The Co-pay Assistance Program is not insurance.**
- The Co-pay Assistance Program form may not be sold, purchased, traded, or counterfeited. Void if reproduced.
- The Co-pay Assistance Program is void where prohibited by law, taxed, or restricted. The Co-pay Assistance Program is not transferable. No substitutions are permitted.
- The Co-pay Assistance Program benefit cannot be combined with any other Co-pay Assistance Program, free trial, discount, prescription savings card, or other offer.
- KabiCare reserves the right to rescind, revoke, or amend the Co-pay Assistance Program at any time without notice.
- Data related to patient's receipt of Co-pay Assistance Program benefits may be collected, analyzed, and shared with KabiCare, for market research and other purposes related to assessing Co-pay Assistance Programs. Data shared with KabiCare will be aggregated and de-identified, meaning it will be combined with data related to other Co-pay Assistance Program redemptions and will not identify patient.
- These Terms and Conditions are valid for Program Product administered between January 1, 2020, and December 31, 2023.
- **Expiration Date: 12/31/2023.**